Back to Search
Start Over
Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup
- Source :
- Journal of Clinical Oncology. 22:3741-3750
- Publication Year :
- 2004
- Publisher :
- American Society of Clinical Oncology (ASCO), 2004.
-
Abstract
- Purpose To evaluate prognostic factors for relapse-free survival (RFS) and overall survival (OS) and to assess the impact of different postremission therapies in adult patients with core binding factor (CBF) acute myeloid leukemias (AML). Patients and Methods Individual patient data–based meta-analysis was performed on 392 adults (median age, 42 years; range, 16 to 60 years) with CBF AML (t(8;21), n = 191; inv(16), n = 201) treated between 1993 and 2002 in prospective German AML treatment trials. Results RFS was 60% and 58% and OS was 65% and 74% in the t(8;21) and inv(16) groups after 3 years, respectively. For postremission therapy, intention-to-treat analysis revealed no difference between intensive chemotherapy and autologous transplantation in the t(8;21) group and between chemotherapy, autologous, and allogeneic transplantation in the inv(16) group. In the t(8;21) group, significant prognostic variables for longer RFS and OS were lower WBC and higher platelet counts; loss of the Y chromosome in male patients was prognostic for shorter OS. In the inv(16) group, trisomy 22 was a significant prognostic variable for longer RFS. For patients who experienced relapse, second complete remission rate was significantly lower in patients with t(8;21), resulting in a significantly inferior survival duration after relapse compared with patients with inv(16). Conclusion We provide novel prognostic factors for CBF AML and show that patients with t(8;21) who experience relapse have an inferior survival duration.
- Subjects :
- Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Pediatrics
Prognostic variable
Adolescent
Acute myeloblastic leukemia
medicine.medical_treatment
Trisomy
Transplantation, Autologous
Disease-Free Survival
Sex Factors
Recurrence
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Transplantation, Homologous
Autologous transplantation
Core binding factor acute myeloid leukemia
Bone Marrow Transplantation
Chemotherapy
business.industry
Core Binding Factor alpha Subunits
Myeloid leukemia
Middle Aged
Prognosis
medicine.disease
DNA-Binding Proteins
Transplantation
Leukemia
Transcription Factor AP-2
Leukemia, Myeloid
Acute Disease
Female
business
Transcription Factors
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....62ec424a03290ec68b493e725ac7014c